ライフサイエンスコーパス: acquired immunodeficiency

1 ell function is disrupted by an inherited or acquired immunodeficiency.

2 y the LP-BM5 retrovirus, which causes murine acquired immunodeficiency.

3 e disease, organ transplants, and primary or acquired immunodeficiencies.

4 icella or zoster associated with primary and acquired immunodeficiencies.

5 pergillosis in children and adolescents with acquired immunodeficiencies and discusses the value of c

6 lignant neoplasias, cardiovascular diseases, acquired immunodeficiencies and other chronic diseases (

7 transplantation, in states of congenital or acquired immunodeficiency, and during normal aging.

8 In acquired immunodeficiency due to the human immunodeficie

9 individuals and in patients with genetic or acquired immunodeficiency (e.g., AIDS) or autoimmune dis

10 In addition to acquired immunodeficiencies like HIV or autoantibodies t

11 in the relative risk of death related to the acquired immunodeficiency syndrome (0.73; 95 percent con

12 uman immunodeficiency virus infection or the acquired immunodeficiency syndrome (7 percent each).

13 study, baseline plasma from 619 persons with acquired immunodeficiency syndrome (AIDS) (median CD4+ l

14 fect of injection drug use on 6-year risk of acquired immunodeficiency syndrome (AIDS) after initiati

15 To investigate the validity of self-reported acquired immunodeficiency syndrome (AIDS) among women en

16 ne their associations with incident clinical acquired immunodeficiency syndrome (AIDS) and CD4+ T cel

17 iciency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed b

18 gnificant reductions in the incidence of the acquired immunodeficiency syndrome (AIDS) and in mortali

19 T) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased

20 pontine myelinolysis), infections [malaria, acquired immunodeficiency syndrome (AIDS) and infection

21 es suggest a correlation between severity of acquired immunodeficiency syndrome (AIDS) and selenium d

22 In 1981, the acquired immunodeficiency syndrome (AIDS) appeared insid

23 Encephalitis and dementia associated with acquired immunodeficiency syndrome (AIDS) are characteri

24 ections of the biliary tree in patients with acquired immunodeficiency syndrome (AIDS) are well known

25 return visit to the clinic and being free of acquired immunodeficiency syndrome (AIDS) at enrollment.

26 ed 13 years or older who were diagnosed with acquired immunodeficiency syndrome (AIDS) between Januar

27 A total of 1600 participants with acquired immunodeficiency syndrome (AIDS) but without CM

28 mimic a clinical trial to assess the risk of acquired immunodeficiency syndrome (AIDS) by timing of t

29 quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the Un

30 ods for estimating the prevented fraction of acquired immunodeficiency syndrome (AIDS) cases attribut

31 lor represent an increasing proportion of US acquired immunodeficiency syndrome (AIDS) cases, few res

32 cterized for certain biliary diseases, e.g., acquired immunodeficiency syndrome (AIDS) cholangiopathy

33 Biliary cryptosporidiosis is associated with acquired immunodeficiency syndrome (AIDS) cholangiopathy

34 ession on CD8(+) T lymphocytes may relate to acquired immunodeficiency syndrome (AIDS) clinical progr

35 ficiency virus (HIV) infections and averting acquired immunodeficiency syndrome (AIDS) deaths in the

36 Declines in the number of acquired immunodeficiency syndrome (AIDS) deaths were fi

37 tions occurred in one patient (25%), all non-acquired immunodeficiency syndrome (AIDs) defining.

38 (HIV)-infected brain in relationship to the acquired immunodeficiency syndrome (AIDS) dementia compl

39 Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in mos

40 human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) epidemic has g

41 se to the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic is th

42 Containment of the acquired immunodeficiency syndrome (AIDS) epidemic will

43 (HIV) vaccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but

44 Early in the acquired immunodeficiency syndrome (AIDS) epidemic, epid

45 networks in predicting rapid progression to acquired immunodeficiency syndrome (AIDS) for patients w

46 In contrast, persons with established acquired immunodeficiency syndrome (AIDS) had a signific

47 ndidate genes for stem cell gene therapy for acquired immunodeficiency syndrome (AIDS) has been limit

48 Persons with acquired immunodeficiency syndrome (AIDS) have a higher

49 ons with cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required

50 r and was mainly due to the emergence of the acquired immunodeficiency syndrome (AIDS) in 25- to 64-y

51 eficiency virus type 1 (HIV-1), the cause of acquired immunodeficiency syndrome (AIDS) in humans, eff

52 SIVsm from sooty mangabeys, are the cause of acquired immunodeficiency syndrome (AIDS) in humans.

53 virus type 1 (HIV-1), the etiologic agent of acquired immunodeficiency syndrome (AIDS) in humans.

54 ently have focused on access to treatment of acquired immunodeficiency syndrome (AIDS) in poor, sever

55 mmunodeficiency virus (HIV) infection or the acquired immunodeficiency syndrome (AIDS) in sub-Saharan

56 n immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) in the federal

57 's Health Study (SFMHS); 268 men without the acquired immunodeficiency syndrome (AIDS) in the SFMHS w

58 iruses, however, SIVs do not generally cause acquired immunodeficiency syndrome (AIDS) in their natur

59 activation is a key factor in progression to acquired immunodeficiency syndrome (AIDS) in untreated H

60 Acquired immunodeficiency syndrome (AIDS) is principally

61 As people with acquired immunodeficiency syndrome (AIDS) live longer, t

62 uals with a high viral set point progress to acquired immunodeficiency syndrome (AIDS) more rapidly t

63 To understand recent temporal trends in acquired immunodeficiency syndrome (AIDS) mortality in t

64 lative risk (RR) for clinical progression to acquired immunodeficiency syndrome (AIDS) of 1.66 (95% c

65 idemic of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) on demand for

66 gosity of class I loci (A, B, and C) delayed acquired immunodeficiency syndrome (AIDS) onset among pa

67 c millimeter or until the development of the acquired immunodeficiency syndrome (AIDS) or another con

68 hly active antiretroviral therapy on time to acquired immunodeficiency syndrome (AIDS) or death in 1,

69 Rates of acquired immunodeficiency syndrome (AIDS) or death on su

70 iretroviral therapy initiation with incident acquired immunodeficiency syndrome (AIDS) or death while

71 ve antiretroviral therapy (HAART) on time to acquired immunodeficiency syndrome (AIDS) or death, the

72 re urgently needed to curb the growth of the acquired immunodeficiency syndrome (AIDS) pandemic and u

73 erapeutic strategies that aim to contain the acquired immunodeficiency syndrome (AIDS) pandemic.

74 The hallmark of acquired immunodeficiency syndrome (AIDS) pathogenesis i

75 V-infected populations compared with similar acquired immunodeficiency syndrome (AIDS) patients in th

76 CSF samples from 15 acquired immunodeficiency syndrome (AIDS) patients with

77 This study reports the surgical outcomes of acquired immunodeficiency syndrome (AIDS) patients with

78 entify cancers that occur at higher rates in acquired immunodeficiency syndrome (AIDS) patients, the

79 tivation and drives systemic inflammation in acquired immunodeficiency syndrome (AIDS) patients.

80 es persistent skin neoplasms in children and acquired immunodeficiency syndrome (AIDS) patients.

81 fection in a new host is a critical goal for acquired immunodeficiency syndrome (AIDS) research.

82 tion analysis of five cohorts of people with acquired immunodeficiency syndrome (AIDS) revealed that

83 Most acquired immunodeficiency syndrome (AIDS) service provid

84 ococcal disease incidence among persons with acquired immunodeficiency syndrome (AIDS) since the intr

85 reduced in alveolar macrophages and PMN from acquired immunodeficiency syndrome (AIDS) subjects, we i

86 The authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 1

87 age is associated with markedly enhanced HIV/acquired immunodeficiency syndrome (AIDS) susceptibility

88 iciency virus (HIV) among cases who obtained acquired immunodeficiency syndrome (AIDS) through hetero

89 nctively associated with communication about acquired immunodeficiency syndrome (AIDS) through social

90 esign, the authors compared 1,642 women with acquired immunodeficiency syndrome (AIDS) to 8,443 uninf

91 ted from monkeys with acute SIV infection or acquired immunodeficiency syndrome (AIDS) underwent norm

92 ed States-based natural-history cohorts with acquired immunodeficiency syndrome (AIDS) were genotyped

93 megalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are receiv

94 affects about 4 percent of patients with the acquired immunodeficiency syndrome (AIDS), and survival

95 se to cryptosporidiosis in patients with the acquired immunodeficiency syndrome (AIDS), and went on t

96 tomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS), but it does n

97 redicts the likelihood of progression to the acquired immunodeficiency syndrome (AIDS), but the relat

98 ere followed from seroconversion to incident acquired immunodeficiency syndrome (AIDS), death, or the

99 ncy virus type 1 (HIV-1), the cause of human acquired immunodeficiency syndrome (AIDS), is a zoonotic

100 ciency virus type 1 (HIV-1) infection to the acquired immunodeficiency syndrome (AIDS), it appears th

101 udy was to measure, as a model of wasting in acquired immunodeficiency syndrome (AIDS), longitudinal

102 eases included in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defi

103 In addition to acquired immunodeficiency syndrome (AIDS), persons infec

104 reduced prevalence and mortality induced by acquired immunodeficiency syndrome (AIDS), provided the

105 inment of deaths among people diagnosed with acquired immunodeficiency syndrome (AIDS), the authors d

106 ctives on human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), tuberculosis

107 and immune activation predict progression to acquired immunodeficiency syndrome (AIDS), we evaluated

108 pe SIV infection in macaques leads to simian Acquired Immunodeficiency Syndrome (AIDS), which does no

109 ly antiretroviral therapy, which can prevent acquired immunodeficiency syndrome (AIDS)-associated eve

110 Patients with acquired immunodeficiency syndrome (AIDS)-associated non

111 virus (SIV)-infected macaques as a model of acquired immunodeficiency syndrome (AIDS)-associated P.

112 The acquired immunodeficiency syndrome (AIDS)-causing lentiv

113 asures were death, the occurrence of a first acquired immunodeficiency syndrome (AIDS)-defining condi

114 Histoplasmosis is among the main acquired immunodeficiency syndrome (AIDS)-defining condi

115 re divided by disease severity defined as an acquired immunodeficiency syndrome (AIDS)-defining event

116 Ten individuals developed acquired immunodeficiency syndrome (AIDS)-defining event

117 definition of LTF on estimated rates of LTF, acquired immunodeficiency syndrome (AIDS)-defining event

118 e antiretroviral therapy (HAART) on multiple acquired immunodeficiency syndrome (AIDS)-defining illne

119 did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illne

120 follow-up; all were antiretroviral-naive and acquired immunodeficiency syndrome (AIDS)-free prior to

121 o identify CD4(+) levels associated with the acquired immunodeficiency syndrome (AIDS)-free time equi

122 The acquired immunodeficiency syndrome (AIDS)-protective che

123 We assessed non-liver-related non-acquired immunodeficiency syndrome (AIDS)-related (NLR-N

124 from eight HCV-infected patients who died of acquired immunodeficiency syndrome (AIDS)-related compli

125 venues for investigating the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related cytope

126 To determine whether microbiologic cure of acquired immunodeficiency syndrome (AIDS)-related dissem

127 and to determine the role that a hospital's acquired immunodeficiency syndrome (AIDS)-related experi

128 munodeficiency virus (HIV) have shifted from acquired immunodeficiency syndrome (AIDS)-related illnes

129 e 1 pilot study of IL-12 in 32 patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi

130 ARL (acquired immunodeficiency syndrome (AIDS)-related lympho

131 osing event in the early pathogenesis of the acquired immunodeficiency syndrome (AIDS)-related lympho

132 ffect of time-varying incident TB on time to acquired immunodeficiency syndrome (AIDS)-related mortal

133 in Kaposi's sarcoma (KS), as well as in some acquired immunodeficiency syndrome (AIDS)-related non-Ho

134 emonstrated that prior to the development of acquired immunodeficiency syndrome (AIDS)-related pulmon

135 mic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I

136 the development of a preventive vaccine for acquired immunodeficiency syndrome (AIDS).

137 ficiency virus (SIV) very rarely progress to acquired immunodeficiency syndrome (AIDS).

138 proportional increases in incidence rates of acquired immunodeficiency syndrome (AIDS).

139 mon opportunistic infection of patients with acquired immunodeficiency syndrome (AIDS).

140 cterial infection in untreated patients with acquired immunodeficiency syndrome (AIDS).

141 macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS).

142 function and its predictors in children with acquired immunodeficiency syndrome (AIDS).

143 may cause chronic diarrhea in patients with acquired immunodeficiency syndrome (AIDS).

144 ied cocaine as a cofactor for development of acquired immunodeficiency syndrome (AIDS).

145 trointestinal disease are common features of acquired immunodeficiency syndrome (AIDS).

146 galovirus retinitis in 160 patients with the acquired immunodeficiency syndrome (AIDS).

147 the main target for design of drugs against acquired immunodeficiency syndrome (AIDS).

148 ant declines in morbidity and mortality from acquired immunodeficiency syndrome (AIDS).

149 ents with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome (AIDS).

150 o be a cofactor in the immunopathogenesis of acquired immunodeficiency syndrome (AIDS).

151 mal viral infectivity and the progression to acquired immunodeficiency syndrome (AIDS).

152 atment of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).

153 t complication of pneumonia in patients with acquired immunodeficiency syndrome (AIDS).

154 ollowing adoptive transfer to a patient with acquired immunodeficiency syndrome (AIDS).

155 sexually transmitted diseases, including the acquired immunodeficiency syndrome (AIDS).

156 er viral loads and more rapid progression to acquired immunodeficiency syndrome (AIDS).

157 s of opportunistic infections related to the acquired immunodeficiency syndrome (AIDS).

158 e and non-Hodgkin's lymphomas related to the acquired immunodeficiency syndrome (AIDS).

159 morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS).

160 groups: adults and children with and without acquired immunodeficiency syndrome (AIDS).

161 ersistent infections in humans which lead to acquired immunodeficiency syndrome (AIDS).

162 HIV infection, is a principal driver of the acquired immunodeficiency syndrome (AIDS).

163 of morbidity and mortality in patients with acquired immunodeficiency syndrome (AIDS).

164 driving force of CD4(+) T-cell depletion and acquired immunodeficiency syndrome (AIDS).

165 advanced human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).

166 actor for HIV-1 infection and progression to acquired immunodeficiency syndrome (AIDS).

167 of the stomach and esophagus in people with acquired immunodeficiency syndrome (AIDS).

168 th species-specific SIVs, but do not develop acquired immunodeficiency syndrome (AIDS).

169 infection since the earliest recognition of acquired immunodeficiency syndrome (AIDS).

170 Five patients had acquired immunodeficiency syndrome (AIDS); one had commo

171 orbid human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) (OR = 4.27

172 h has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and t

173 Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is one of

174 ch as diabetes, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), arthritis

175 illimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defini

176 0, CI 0.28-0.57) and increased with comorbid acquired immunodeficiency syndrome (OR 4.52, CI 3.01-6.7

177 lementation has on the progression of simian acquired immunodeficiency syndrome (SAIDS).

178 ders, and infectious diseases (excluding the acquired immunodeficiency syndrome [AIDS]), many of whic

179 Fifty-nine percent had the acquired immunodeficiency syndrome according to the case

180 interferon (rIFN)- gamma 1b in patients with acquired immunodeficiency syndrome and acute cryptococca

181 from culture isolates from 87 patients with acquired immunodeficiency syndrome and CMV retinitis who

182 rnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis.

183 they had an increased risk of progression to acquired immunodeficiency syndrome and death, a relation

184 sis is classically reported in patients with acquired immunodeficiency syndrome and emerged as a caus

185 regular alcohol consumption (one of whom had acquired immunodeficiency syndrome and hepatitis B), one

186 and clinical parameters among patients with acquired immunodeficiency syndrome and histoplasmosis in

187 ts with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious

188 rden created by human immunodeficiency virus/acquired immunodeficiency syndrome and other infectious

189 rates of incarceration and reported cases of acquired immunodeficiency syndrome and syphilis were wea

190 Records of people diagnosed with acquired immunodeficiency syndrome between 1993 and 2007

191 TB accelerates acquired immunodeficiency syndrome by increasing human i

192 he basic package of services provided by HIV/acquired immunodeficiency syndrome care and treatment pr

193 In patients with sclerosing cholangitis and acquired immunodeficiency syndrome cholangiopathy, MRCP

194 (International Maternal Pediatric Adolescent Acquired Immunodeficiency Syndrome Clinical Trials [IMPA

195 s were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group

196 men who were participants in the Multicenter Acquired Immunodeficiency Syndrome Cohort Study for GBV-

197 es brain function and presents clinically as acquired immunodeficiency syndrome dementia complex (ADC

198 vanced immunodeficiency, all 4 subjects with acquired immunodeficiency syndrome dementia complex had

199 The proportion of acquired immunodeficiency syndrome diagnoses in which wa

200 Having an acquired immunodeficiency syndrome diagnosis or multiple

201 ntigen genetic association with HIV-1 and/or acquired immunodeficiency syndrome disease progression i

202 fies clinical presentation in the era of the acquired immunodeficiency syndrome epidemic.

203 rus type 1 (HIV-1) and those affected by the acquired immunodeficiency syndrome epidemic.

204 ted from 2 ALIVE scientists and an expert in acquired immunodeficiency syndrome epidemiology about th

205 potential therapeutic target to prevent non-acquired immunodeficiency syndrome events.

206 r patients attending a county outpatient HIV/acquired immunodeficiency syndrome facility were referre

207 ciency virus (HIV)-infected subjects without acquired immunodeficiency syndrome have a high frequency

208 Although the incidence of and mortality from acquired immunodeficiency syndrome have declined recentl

209 t the LP-BM5 murine leukemia virus causes an acquired immunodeficiency syndrome in C57BL/6 mice (MAID

210 rculosis is often the first manifestation of acquired immunodeficiency syndrome in patients infected

211 gene therapy strategies for diseases such as acquired immunodeficiency syndrome is limited.

212 cted injection drug users recruited into the Acquired Immunodeficiency Syndrome Link to Intravenous E

213 Deaths from acquired immunodeficiency syndrome occurred exclusively

214 to initiate therapy prior to progression to acquired immunodeficiency syndrome or death by both meas

215 ts of dropout, the weighted hazard ratio for acquired immunodeficiency syndrome or death comparing us

216 ly active antiretroviral therapy on incident acquired immunodeficiency syndrome or death, the authors

217 active antiretroviral therapy, 211 developed acquired immunodeficiency syndrome or died, and 173 drop

218 r patients with human immunodeficiency virus/acquired immunodeficiency syndrome or substance abuse (f

219 ings has begun to mitigate the impact of the acquired immunodeficiency syndrome pandemic.

220 anciclovir has become increasingly common in acquired immunodeficiency syndrome patients but has only

221 the spinal cord dorsal horn (SDH) from HIV-1/acquired immunodeficiency syndrome patients who develope

222 revious serologic diagnosis of HIV, from the acquired immunodeficiency syndrome program of the Health

223 iation between HCV and MI in the Centers for Acquired Immunodeficiency Syndrome Research Network of I

224 subtyping is not integrated into routine HIV/acquired immunodeficiency syndrome surveillance in the U

225 virus induces a complex disease featuring an acquired immunodeficiency syndrome termed murine AIDS (M

226 aracterized by slower disease progression to acquired immunodeficiency syndrome than results from HIV

227 eficiency virus (HIV) protease inhibitors in acquired immunodeficiency syndrome therapy.

228 interferon era (using data from the European Acquired Immunodeficiency Syndrome Treatment Network [NE

229 relevance of their epitopes in the design of acquired immunodeficiency syndrome vaccines.

230 tions of measles in the setting of a chronic acquired immunodeficiency syndrome virus infection.

231 eys were used to clarify the distribution of acquired immunodeficiency syndrome virus-specific cytoto

232 age of > 10% and a positive association with acquired immunodeficiency syndrome were borderline signi

233 R, 0.2; 95% CI, 0.03-0.9), but patients with acquired immunodeficiency syndrome were more likely to r

234 eukemia, lymphoma, severe liver disease, and acquired immunodeficiency syndrome were rarely identifie

235 ination of brain tissue from 2 patients with acquired immunodeficiency syndrome who had CMV encephali

236 chieving immune restoration in patients with acquired immunodeficiency syndrome who have incomplete r

237 8 lymphocytes/mm(3)), 90 (18%) progressed to acquired immunodeficiency syndrome within 5 years.

238 st a close friend or intimate partner to the acquired immunodeficiency syndrome within the prior 6 mo

239 inhibitors against HIV, the culprit of AIDS (acquired immunodeficiency syndrome).

240 ed ART; 5 patients died (unrelated to HIV or acquired immunodeficiency syndrome).

241 5,321 person-years, 268 of 614 men incurred acquired immunodeficiency syndrome, 49 died, and 90 were

242 load after infection and 5-year incidence of acquired immunodeficiency syndrome, adjusting for (conti

243 eme Court's first case involving HIV and the acquired immunodeficiency syndrome, Bragdon v Abbott, ad

244 However, the acquired immunodeficiency syndrome, breast cancer, diabe

245 en-group differences in the incidence of the acquired immunodeficiency syndrome, death, or serious ad

246 tors for NTS, including autoimmune diseases, acquired immunodeficiency syndrome, diabetes, cirrhosis,

247 HIV-2, a human pathogen that causes acquired immunodeficiency syndrome, is distinct from the

248 type 1 reduces the mortality of persons with acquired immunodeficiency syndrome, it does not eliminat

249 In nonhuman primate models of acquired immunodeficiency syndrome, live attenuated lent

250 man immunodeficiency virus infection and the acquired immunodeficiency syndrome, medical malpractice,

251 g patients with human immunodeficiency virus/acquired immunodeficiency syndrome, patients receiving t

252 n human immunodeficiency virus infection and acquired immunodeficiency syndrome, rheumatoid arthritis

253 The mean reporting completeness for acquired immunodeficiency syndrome, sexually transmitted

254 In acquired immunodeficiency syndrome, the retina is a majo

255 rvum is a major problem in patients with the acquired immunodeficiency syndrome, the specific microbi

256 the worldwide health problems caused by the acquired immunodeficiency syndrome, tuberculosis, and ma

257 uman immunodeficiency virus infection or the acquired immunodeficiency syndrome, were referred to the

258 s, malaria, and human immunodeficiency virus/acquired immunodeficiency syndrome, with significant res

259 fection causes an AIDS-like syndrome--murine acquired immunodeficiency syndrome--in C57B1/6 mice and

260 to neonatal infection, transplantation, and acquired immunodeficiency syndrome-associated CMV diseas

261 The acquired immunodeficiency syndrome-associated lymphoma A

262 reducing the disease burden in patients with acquired immunodeficiency syndrome-associated tuberculos

263 00 x 10(6)/L and 549 x 10(6)/L without prior acquired immunodeficiency syndrome-defining conditions r

264 ficantly higher for patients without a prior acquired immunodeficiency syndrome-defining illness and

265 tion, whereas patients who developed another acquired immunodeficiency syndrome-defining illness did

266 s were used to determine predictors of a new acquired immunodeficiency syndrome-defining illness or d

267 nts with Medicaid, and patients with a prior acquired immunodeficiency syndrome-defining illness were

268 ive multifocal leukoencephalopathy (PML), an acquired immunodeficiency syndrome-defining illness.

269 infection and CIN, and cervical cancer is an acquired immunodeficiency syndrome-defining illness.

270 r, and 65 percent of the patients had had an acquired immunodeficiency syndrome-defining illness.

271 1984-2008, regarding estimation of long-term acquired immunodeficiency syndrome-free survival to demo

272 ococcal meningitis accounts for 20 to 25% of acquired immunodeficiency syndrome-related deaths in Afr

273 imately 25% of patients with newly diagnosed acquired immunodeficiency syndrome-related lymphoma (ARL

274 ived a heterologous stem cell transplant for acquired immunodeficiency syndrome-related lymphoma from

275 The outcome of acquired immunodeficiency syndrome-related lymphomas (AR

276 Recent dramatic decreases in acquired immunodeficiency syndrome-related mortality are

277 was used to evaluate the effect of HAART on acquired immunodeficiency syndrome-related mortality, ad

278 Because the incidence of traditional acquired immunodeficiency syndrome-related opportunistic

279 h human immunodeficiency virus (HIV) but not acquired immunodeficiency syndrome.

280 ciency virus (SIV)-infected macaque model of acquired immunodeficiency syndrome.

281 compromised patients with cancer or advanced acquired immunodeficiency syndrome.

282 (>/=2 symptoms), and deaths were ascribed to acquired immunodeficiency syndrome.

283 al failure, and human immunodeficiency virus/acquired immunodeficiency syndrome.

284 voirs for viral persistence in patients with acquired immunodeficiency syndrome.

285 carinii DHPS mutations in 107 patients with acquired immunodeficiency syndrome.

286 as been approved by the FDA for treatment of acquired immunodeficiency syndrome.

287 larly in the context of immunodeficiency and acquired immunodeficiency syndrome.

288 n immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.

289 iciency virus infection and delayed onset of acquired immunodeficiency syndrome.

290 regenerative states, immune cytopenias, and acquired immunodeficiency syndrome.

291 ts have been described only in patients with acquired immunodeficiency syndrome.

292 using SSRI treatment adjunctively in HIV and acquired immunodeficiency syndrome.

293 on opportunistic infections in patients with acquired immunodeficiency syndrome.

294 ing to the vascular injury syndromes seen in acquired immunodeficiency syndrome.

295 rus infection, particularly in patients with acquired immunodeficiency syndrome.

296 h cytomegalovirus-associated esophagitis and acquired immunodeficiency syndrome.

297 er nonmalignant CNS lesions in patients with acquired immunodeficiency syndrome.

298 cell counts <350 cells/mm(3) and 2 (7%) had acquired immunodeficiency syndrome.

299 re much rarer than TB, but the inherited and acquired immunodeficiencies underlying these infections

300 cluding hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NAD